BOSTON GLOBE - The sum includes $20 million in venture capital from investors such as New Hampshire-based Novalis LifeSciences and Boston-based Romulus Capital. It also includes a $14 million growth capital term loan from Bridge Bank that Allurion’s chief executive said was a vote of confidence in its product. [...] Marijn Dekkers, the founder and chairman of Novalis LifeSciences and former chief executive of Bayer and Thermo Fisher Scientific, said Allurion is taking a “cutting-edge approach to one of the world’s largest unmet medical needs.”